(Q36617335)

15 August 2017

The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer (English)

1 reference

15 August 2017

1 reference

1 reference

1 reference

Dowsett M

1

1 reference

15 August 2017

Tobias JS

2

1 reference

15 August 2017

Howell A

3

1 reference

15 August 2017

Blackman GM

4

1 reference

15 August 2017

Welch H

5

1 reference

15 August 2017

King N

6

1 reference

15 August 2017

Ponzone R

7

1 reference

15 August 2017

von Euler M

8

1 reference

15 August 2017

Baum M

9

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 January 1999

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

79

1 reference

15 August 2017

2

1 reference

15 August 2017

311-315

1 reference

Recent advances in endocrine therapy of breast cancer

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362190

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362190

New endocrine therapies for breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362190

Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362190

A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362190

Arimidex: a potent and selective fourth-generation aromatase inhibitor

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362190

Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362190

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362190

Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes

20 September 2018

1 reference

12 December 2020

Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide

1 reference

12 December 2020

Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer

1 reference

12 December 2020

Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route

1 reference

12 December 2020

A randomised trial of tamoxifen versus tamoxifen with aminoglutethimide in post-menopausal women with advanced breast cancer

1 reference

12 December 2020

Serum concentrations of tamoxifen and major metabolite during long-term nolvadex therapy, correlated with clinical response

1 reference

12 December 2020

Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer

1 reference

12 December 2020

Adjuvant therapy for breast cancer: understanding the overview. International Breast Cancer Study Group

1 reference

12 December 2020

The preclinical pharmacology of "Arimidex" (anastrozole; ZD1033)--a potent, selective aromatase inhibitor

1 reference

12 December 2020

Reduced recurrence-free survival after reduced doses of adjuvant chemotherapy in breast cancer: are groups selected after randomization comparable?

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690050

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/SJ.BJC.6690050

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

9888474

1 reference